Elsilimomab, with the CAS number 468715-71-1, is a monoclonal antibody that primarily targets the CD3 receptor on T cells. This characteristic makes it a valuable tool in immunotherapy, particularly in the context of autoimmune diseases and certain types of cancer. As a humanized IgG1 antibody, it is designed to minimize immunogenicity while maintaining efficacy. Elsilimomab functions by modulating T cell activity, which can enhance the immune response against tumor cells or alter the immune system's activity in autoimmune conditions. Its mechanism of action involves binding to the CD3 complex, leading to T cell activation and proliferation. The substance is typically administered via injection and is subject to rigorous clinical testing to evaluate its safety and effectiveness. As with many monoclonal antibodies, potential side effects may include infusion reactions and immune-related adverse events. Overall, elisilimomab represents a significant advancement in targeted therapies, showcasing the potential of monoclonal antibodies in modern medicine.

Elsilimomab

468715-71-1: B-E8, Immunoglobulin G1, anti-(human interleukin 6) (mouse hybridoma B-E8 κ-chain), MAB B-E8, Antibody B-E8, Elsilimomab

A recombinant mouse monoclonal antibody to interleukin-6.

Elsilimomab (B-E8) is a monoclonal antibody targeting IL-6, inhibiting the induction of bone marrow stromal cell senescence by dnmt3a mutation clones.

CAS 468715-71-1: Elsilimomab

Elsilimomab

Ref: 3D-CLA1205

Elsilimomab

Ref: TM-T76803